Menu ×

HEALTHCARE & PHARMACEUTICAL

Oncolytic Virus Therapy Market Segmentation by Therapy Type {HSV-based Oncolytic Virus Therapy, Adenovirus-based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), and Others}; by Virus Type (Oncolytic Wild Type Viruses, and Genetically Engineered Oncolytic Viruses); by Indication (Head & Neck, Lung, Kidney, Liver, Pancreatic, Breast, and Colorectal Cancers, Sarcoma, Melanoma); by Demography; and by End-User – Global Demand Analysis & Opportunity Outlook 2019-2028

  • Text Size:

Extensive insights into the Growth of Oncolytic Virus Therapy Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • August 28, 2020: Lokon Pharma AB announced that it has partnered with Roche to evaluate the immunostimulatory armed gene therapy virus of Lokon, LOAd703, in combination with the programmed cell death ligand 1 (PD-L1)-blocking checkpoint inhibitor (CPI) of Roche, Tecentriq, in the patients suffering from metastatic colorectal cancer.

Global Oncolytic Virus Therapy Market Highlights Over 2019 - 2028

The global oncolytic virus therapy market is estimated to grow with a CAGR of 27.29% over the forecast period, i.e., 2021 – 2028. The growth of the market can primarily be attributed to the rising incidences of cancer and for the need to cure such chronic diseases. According to the statistics by the World Health Organization (WHO), globally, cancer is the leading cause of deaths and in the year 2020, it accounted for about 10 Million deaths. Out of the most common new cancer cases in the year 2020, breast and lung cancer held the highest share, registering 2.26 Million cases and 2.21 Million cases respectively. Cancer incidences have risen steadily across the world owing to the growing and aging population globally, and for the increasing exposure to cancer risk factors. The rising concern for such cases is driving the need for advanced cancer detection and treatment procedures, which is expected to contribute to the growth of the market during the forecast period. The global oncolytic virus therapy market garnered a revenue of USD 160.4 Million in the year 2019 and is further expected to touch USD 1062.7 Million by the end of 2028.

oncolytic virus therapy market GraphMoreover, the rising demand for targeted cancer therapies, backed by the rapid advancements in cancer research, and the surge in approval of immuno-oncology drugs by the medical fraternities, are also expected to accelerate the market growth in the coming years. Furthermore, rising healthcare expenditure, which according to the World Bank, as a share of GDP, grew from 9.417% in 2013 to 9.857% in 2018, is also one of the major factors anticipated to drive the market growth. CLICK TO DOWNLOAD SAMPLE REPORT

Current Health Expenditure Graph

Global Oncolytic Virus Therapy Market Regional Synopsis

Regionally, the global oncolytic virus therapy market is segmented into North America, Europe, Asia Pacific, and the Rest of World. Amongst the market in these regions, the market in North America is projected to hold the highest market share during the forecast period. In 2019, the market in the region garnered a revenue of USD 68.5 Million, and is further projected to reach USD 509.4 Million by the end of 2028. Rising awareness amongst individuals for different cancer treatments, increasing availability of advanced immune-oncology drugs in the region, along with the growing healthcare spending in countries such as the United States, are some of the major factors anticipated to drive the market growth in the region. According to the statistics by the American Cancer Society, in the United States, around 1.9 Million new cancer cases are expected to be diagnosed. Further, around 608570 deaths caused due to cancer is expected in the country in the same year.

The market in Europe, on the other hand, is expected to garner the second-largest market revenue of USD 295.5 Million by the end of 2028. Amongst the countries in the region, the market in the United Kingdom is projected to garner the largest market revenue of USD 83.1 Million by the end of 2028 by growing from a revenue of USD 10.8 Million in 2019.

Growth Drivers and Challenges Impacting the Growth of the Global Oncolytic Virus Therapy Market

Growth Drivers

  • Growing Cancer Cases Worldwide
  • Increasing Demand for Targeted Therapy
  • Rising Healthcare Expenditure Globally
  • Rapid Advancements in Healthcare Research

Challenges

  • Stringent Regulatory Standards
  • High Cost of Cancer Drug Development

Global Oncolytic Virus Therapy Market Segmentation Synopsis

The global oncolytic virus therapy market is segmented by therapy type into HSV-based oncolytic virus therapy, adenovirus-based oncolytic virus therapy, reovirus, poxviruses, Newcastle disease virus (NDV), and others. Amongst these segments, the adenovirus-based oncolytic virus therapy segment held the highest market share of 30.2% in the year 2019 and is further projected to attain a significant market share by the end of 2028. On the basis of virus type, the market is segmented into oncolytic wild type viruses and genetically engineered oncolytic viruses, out of which, the genetically engineered oncolytic viruses segment is expected to hold the largest market share throughout the forecast period. Further, based on virus type, the market is segmented into head & neck cancer, lung cancer, kidney cancer, liver cancer, pancreatic cancer, breast cancer, colorectal cancer, sarcoma, melanoma, and others. Out of these, the colorectal cancer segment registered the second-highest market share of 11.1% in the year 2019. The segment is further expected to attain a significant market revenue by the end of 2028. On the basis of demography, the market is segmented into adults and pediatric, out of which, the adults segment is projected to gain the highest market share throughout the forecast period. The market is also segmented on the basis of end of end-user into hospitals, specialty clinics, and cancer research institutes, out of which, the hospitals segment held the highest market share of 46.60% in the year 2019.

Key Companies Dominating the Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global oncolytic virus therapy market that are included in our report are Amgen Inc., Shanghai Sunway Biotech Co., Ltd., Oncolys BioPharma Inc., TILT Biotherapeutics Ltd., Oncorus, Inc., Takara Bio Inc., Vyriad, Transgene sa, Lokon Pharma AB, Pfizer Inc., and others.

Key Reasons to Buy Our Report

  • The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
  • It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
  • The report includes detailed company profiles of the major players dominating the market.
  • We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
  • We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.

FREQUENTLY ASKED QUESTIONS

  1. Introduction
    1. Market Definition
    2. Market Segmentation
    3. Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. End-Users
    3. Secondary Research
    4. Market Size Estimation
  4. Executive Summary - Global Oncolytic Virus Therapy Market (2019-2028)
  5. Analysis of Market Dynamics
    1. Growth drivers  
    2. Opportunities
    3. Market Trends
    4. Restraints
  6. Regulatory & Standards Landscape
    1. Manufacturing Standards & Compliances
    2. Environmental Compliances
  7. Analysis on the Mechanism of Oncolytic Virus Therapy
  8. Recent Developments in Oncolytic Virus Therapy Market
  9. Pipeline Analysis
    1. Clinical Trial Outlook
  10. Epidemiology Analysis
  11. Oncolytic Virus Platforms Under Evaluation
    1. Adenovirus
    2. Herpes Simplex Virus
    3. Maraba Virus
    4. Measles
    5. Newcastle Disease Virus
    6. Others
  12. Impact of COVID-19 on the Oncolytic Virus Therapy Market
    1. Impact of COVID-19 on the Overall Healthcare Sector
    2. Impact on Demand
    3. Impact on the Cancer Treatment
    4. Impact on the Manufacturers
    5. Impact on the Research & Development Activities
    6. Impact on the Product Pipeline
    7. Impact on the Key Market Players
    8. Impact on the New Entrants in the Market
    9. Impact on the Pricing
    10. Market Impact Analysis in 2020 (quarter wise) w.r.t COVID-19 Pandemic (USD Million)
  13. Analysis on the Oncolytic Virus Therapy
  14. Analysis on the Oncolytic Virus Therapy Cost, USD
  15. End-User Analysis
  16. Competitive Structure (Both Marketed and Pipeline Drugs)
    1. Market Share Analysis, 2020
    2. Profiled Companies
      1. Amgen Inc.
      2. Shanghai Sunway Biotech Co., Ltd.
      3. Oncolys BioPharma Inc.
      4. TILT Biotherapeutics Ltd.
      5. Oncorus, Inc.
      6. Takara Bio Inc.
      7. Vyriad
      8. Transgene sa
      9. Lokon Pharma AB
      10. Pfizer Inc.
  17. Oncolytic Virus Therapy Market Outlook
    1. By Value (USD Million)
  18. Oncolytic Virus Therapy Market Segmentation Analysis 2019-2028
    1. By Therapy Type
      1. HSV-Based Oncolytic Virus Therapy, 2019-2028F (USD Million)
      2. Adenovirus-Based Oncolytic Virus Therapy, 2019-2028F (USD Million)
      3. Reovirus
      4. Poxviruses
      5. NDV (Newcastle Disease Virus)
      6. Others (Measles Virus; HVJ-E; SVV; Retrovirus; Parvovirus; Gamma-herpes Virus)
    2. By Virus Type
      1. Oncolytic Wild Type Viruses, 2019-2028F (USD Million)
      2. Genetically Engineered Oncolytic Viruses, 2019-2028F (USD Million)
    3. By Indication
      1. Head & Neck Cancer, 2019-2028F (USD Million)
      2. Lung Cancer, 2019-2028F (USD Million)
      3. Kidney Cancer, 2019-2028F (USD Million)
      4. Liver Cancer, 2019-2028F (USD Million)
      5. Pancreatic Cancer, 2019-2028F (USD Million)
      6. Breast Cancer, 2019-2028F (USD Million)
      7. Colorectal Cancer, 2019-2028F (USD Million)
      8. Sarcoma, 2019-2028F (USD Million)
        1. Bone Cancer, 2019-2028F (USD Million)
        2. Angiosarcoma, 2019-2028F (USD Million)
        3. Fibrosarcoma, 2019-2028F (USD Million)
        4. Leiomyosarcoma, 2019-2028F (USD Million)
        5. Others, 2019-2028F (USD Million)
      9. Melanoma, 2019-2028F (USD Million)
      10. Others, 2019-2028F (USD Million)
    4. By Demography
      1. Pediatric, 2019-2028F (USD Million)
      2. Adults, 2019-2028F (USD Million)
    5. By End-User
      1. Hospitals, 2019-2028F (USD Million)
      2. Hospitals, 2019-2028F (USD Million)
      3. Cancer Research Institutes, 2019-2028F (USD Million)
  19. Oncolytic Virus Therapy Market, By Region, 2019-2028
    1. North America, 2019-2028F (USD Million): U.S.
    2. Europe, 2019-2028F (USD Million): Germany, U.K., France, Italy, Spain and Rest of Europe
    3. Asia Pacific, 2019-2028F (USD Million): China, Japan, Australia and Rest of Asia-Pacific
    4. Rest of World, 2019-2028F (USD Million)
  20. Regional Oncolytic Virus Therapy Market Outlook (North America, Europe, Asia-Pacific and Rest of World)
    1. Leading Companies in Oncolytic Virus Therapy Market
    2. Assessment of macroeconomic factors
    3. Analysis on the Development of Oncolytic Virus Therapies
  21. Global & Regional Oncological Market Overview (2019-2028)

Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved